AZ, Takeda, Novartis Praised For Medicines Access Work But More Is Needed
Executive Summary
The 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing, says a new report from the Access to Medicine Foundation.